Literature DB >> 24972966

MiR-26a inhibits prostate cancer progression by repression of Wnt5a.

Shijia Zhao1, Xiangdong Ye, Lei Xiao, Xuexiong Lian, Yupeng Feng, Feng Li, Li Li.   

Abstract

MicroRNAs (miRNAs) are small noncoding RNAs that are involved in different biological processes by suppressing target gene expression. miRNA microarray analysis revealed a significant decrease of miR-26a in prostate cancer tissues versus their normal counterparts, but the role of miR-26a is needed to investigate. In the present study, we found that miR-26a expression was lower in prostate cancer tissues compared with their normal controls, so did the prostate cancer cells. Next, by lentivirus-mediated gain-of-function studies, it was showed that stable miR-26a inhibited cell proliferation, metastasis, and epithelial mesenchymal transition and induced G1 phase arrest in prostate cancer. It was predicted that Wnt5a was a potential target gene of miR-26a by bioinformatics analysis. Then, luciferase assay and Western blot analysis identified that Wnt5a was a new direct target gene of miR-26a and miR-26a inhibited prostate cancer progression via Wnt5a. Altogether, the findings suggested that miR-26a may function as a tumor suppressor in prostate cancer by targeting Wnt5a.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24972966     DOI: 10.1007/s13277-014-2206-4

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  27 in total

1.  Expression profile analysis reveals putative prostate cancer-related microRNAs.

Authors:  H Song; Y Liu; J Pan; S T Zhao
Journal:  Genet Mol Res       Date:  2013-10-24

Review 2.  The economic burden of prostate cancer.

Authors:  Claus G Roehrborn; Libby K Black
Journal:  BJU Int       Date:  2011-09       Impact factor: 5.588

Review 3.  Regulation of epithelial-mesenchymal and mesenchymal-epithelial transitions by microRNAs.

Authors:  Samy Lamouille; Deepa Subramanyam; Robert Blelloch; Rik Derynck
Journal:  Curr Opin Cell Biol       Date:  2013-02-20       Impact factor: 8.382

4.  Widespread deregulation of microRNA expression in human prostate cancer.

Authors:  M Ozen; C J Creighton; M Ozdemir; M Ittmann
Journal:  Oncogene       Date:  2007-09-24       Impact factor: 9.867

5.  Ectopic expression of miR-126*, an intronic product of the vascular endothelial EGF-like 7 gene, regulates prostein translation and invasiveness of prostate cancer LNCaP cells.

Authors:  Alla Musiyenko; Vira Bitko; Sailen Barik
Journal:  J Mol Med (Berl)       Date:  2008-01-12       Impact factor: 4.599

Review 6.  Epithelial-mesenchymal transition (EMT): principles and clinical impact in cancer therapy.

Authors:  María Liliana Franco-Chuaire; Sánchez-Corredor Magda Carolina; Lilian Chuaire-Noack
Journal:  Invest Clin       Date:  2013-06       Impact factor: 0.683

7.  MicroRNA-21 directly targets MARCKS and promotes apoptosis resistance and invasion in prostate cancer cells.

Authors:  Tao Li; Dong Li; Jianjun Sha; Peng Sun; Yiran Huang
Journal:  Biochem Biophys Res Commun       Date:  2009-03-18       Impact factor: 3.575

8.  Myc enforces overexpression of EZH2 in early prostatic neoplasia via transcriptional and post-transcriptional mechanisms.

Authors:  Cheryl M Koh; Tsuyoshi Iwata; Qizhi Zheng; Carlise Bethel; Srinivasan Yegnasubramanian; Angelo M De Marzo
Journal:  Oncotarget       Date:  2011-09

Review 9.  Competing endogenous RNAs (ceRNAs): new entrants to the intricacies of gene regulation.

Authors:  Reena V Kartha; Subbaya Subramanian
Journal:  Front Genet       Date:  2014-01-30       Impact factor: 4.599

Review 10.  Epithelial-mesenchymal plasticity in carcinoma metastasis.

Authors:  Jeff H Tsai; Jing Yang
Journal:  Genes Dev       Date:  2013-10-15       Impact factor: 11.361

View more
  28 in total

Review 1.  Onco-GPCR signaling and dysregulated expression of microRNAs in human cancer.

Authors:  Nijiro Nohata; Yusuke Goto; J Silvio Gutkind
Journal:  J Hum Genet       Date:  2016-10-13       Impact factor: 3.172

2.  miR-26a inhibits the proliferation of ovarian cancer cells via regulating CDC6 expression.

Authors:  Ting-Yi Sun; Hong-Jian Xie; Hui He; Zhen Li; Ling-Fei Kong
Journal:  Am J Transl Res       Date:  2016-02-15       Impact factor: 4.060

3.  miR-26a suppresses EMT by disrupting the Lin28B/let-7d axis: potential cross-talks among miRNAs in IPF.

Authors:  Haihai Liang; Shanshan Liu; Yang Chen; Xue Bai; Li Liu; Yuechao Dong; Meiyu Hu; Xiaomin Su; Yingzhun Chen; Longtao Huangfu; Xuelian Li; Yunyan Gu; Hongli Shan
Journal:  J Mol Med (Berl)       Date:  2016-01-20       Impact factor: 4.599

4.  Downregulated microRNA-26a modulates prostate cancer cell proliferation and apoptosis by targeting COX-2.

Authors:  Jing Zhang; Jinghao Liang; Jianguo Huang
Journal:  Oncol Lett       Date:  2016-08-31       Impact factor: 2.967

5.  Serum miR-26a as a diagnostic and prognostic biomarker in cholangiocarcinoma.

Authors:  Li-Juan Wang; Kai-Liang Zhang; Ning Zhang; Xiang-Wei Ma; Su-Wen Yan; Dong-Hua Cao; Sheng-Jia Shi
Journal:  Oncotarget       Date:  2015-07-30

6.  MiR-26a and miR-138 block the G1/S transition by targeting the cell cycle regulating network in prostate cancer cells.

Authors:  Kati Erdmann; Knut Kaulke; Christiane Rieger; Karsten Salomo; Manfred P Wirth; Susanne Fuessel
Journal:  J Cancer Res Clin Oncol       Date:  2016-08-25       Impact factor: 4.553

7.  Loss of miR-26a-5p promotes proliferation, migration, and invasion in prostate cancer through negatively regulating SERBP1.

Authors:  Kai Guo; Shaobo Zheng; Yawen Xu; Abai Xu; Binshen Chen; Yong Wen
Journal:  Tumour Biol       Date:  2016-07-23

Review 8.  The role of microRNA-26a in human cancer progression and clinical application.

Authors:  Jing Chen; Kai Zhang; Yuejuan Xu; Yanping Gao; Chen Li; Rui Wang; Longbang Chen
Journal:  Tumour Biol       Date:  2016-04-02

Review 9.  WNT-5A: signaling and functions in health and disease.

Authors:  Kuldeep Kumawat; Reinoud Gosens
Journal:  Cell Mol Life Sci       Date:  2015-10-29       Impact factor: 9.261

10.  Regulation of lipid synthesis by the RNA helicase Mov10 controls Wnt5a production.

Authors:  W Wang; N Snyder; A J Worth; I A Blair; E S Witze
Journal:  Oncogenesis       Date:  2015-06-01       Impact factor: 7.485

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.